It is noteworthy that the expression of Cav-1 in CAFs rather than tumor cells particularly applicable in predicting early recurrence and poor survival prospects of GC patients, suggesting Cav-1 in CAFs may be a candidate therapeutic target and a useful prognostic marker of GC patients. The gene discussed is CAV1; the disease is neoplasm.